AZD0837 + Vitamin-K antagonist at INR 2-3 + AZD0837
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonvalvular Atrial Fibrillation
Conditions
Nonvalvular Atrial Fibrillation
Trial Timeline
Feb 1, 2007 → Jun 1, 2008
NCT ID
NCT00684307About AZD0837 + Vitamin-K antagonist at INR 2-3 + AZD0837
AZD0837 + Vitamin-K antagonist at INR 2-3 + AZD0837 is a phase 2 stage product being developed by AstraZeneca for Nonvalvular Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT00684307. Target conditions include Nonvalvular Atrial Fibrillation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00684307 | Phase 2 | Completed |
Competing Products
6 competing products in Nonvalvular Atrial Fibrillation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0837 + VKA INR 2-3 | AstraZeneca | Phase 2 | 52 |
| Certoparin | Novartis | Phase 3 | 77 |
| Eliquis | Pfizer | Pre-clinical | 22 |
| Apixaban | Bristol Myers Squibb | Pre-clinical | 22 |
| Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA) | Bayer | Pre-clinical | 20 |
| Rivaroxaban 20 MG + Warfarin | Bayer | Approved | 82 |